7-14 | Doctors Without Borders/Médecins Sans Frontières (MSF) denounced the exorbitant price governments and non-governmental organisations are required to pay to vaccinate vulnerable children. In the past few weeks, MSF has vaccinated more than 5,000 refugee children between ages six months and 15 years of age in several camps and settlements across Greece. MSF vaccinated refugee children against ten diseases, including pneumonia.
5-26 | Two years since the first signs of the West Africa Ebola outbreak, the world today is little more prepared to respond to such an emergency than it was then, warns international humanitarian aid organisation Médecins Sans Frontières (MSF), while the lack of R&D into needed medicines and exorbitant medicine prices requires urgent and united action from the world leaders gathered in Japan. Global Health Systems: ‘Don’t build a hospital without an emergency room’ As the leaders of the G7 countries* gather in Ise-Shim
3-21 | Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).
3-11 | Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a ‘patent opposition’ in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organisations.
2-24 | More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of US$1,700 per treatment course.